Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Aldeyra Therapeutics, Inc. | Director | Common Stock | 922 | $9.34K | $10.13 | Apr 12, 2023 | Direct |
4D Molecular Therapeutics, Inc. | Director | Stock Option (Right To Buy) | 22.5K | May 21, 2024 | Direct | ||
Aldeyra Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 1.74K | Jun 4, 2024 | Direct | ||
INTERCEPT PHARMACEUTICALS, INC. | Director | Common Stock | 0 | $19.00 | Nov 8, 2023 | Direct | |
INTERCEPT PHARMACEUTICALS, INC. | Director | Option to Purchase Common Stock | 0 | Nov 8, 2023 | Direct | ||
Kadmon Holdings, Inc. | Director | Stock Option (right to buy) | 0 | $5.54 | Nov 9, 2021 | Direct |